Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, as a warm and shiny sun envelopes the Pharmalot campus. Moreover, a calming quiet has taken hold, now that the short people have left for their respective destinations — the local schoolhouse and gainful employment. All of which means we have an opportunity to catch up on our to-do list and dig in for another busy day. No doubt, you may relate. So here are a few items of interest to get you started. Hope all goes well today and, as always, do keep in touch …

AstraZeneca (AZN) has suspended investments in the U.K. due to the lack of clarity over the country’s looming departure from the European Union, Le Monde says. “If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest,” non-executive chairman Leif Johansson tells the paper. The drug maker has already spent more than $50 million stockpiling medicines in the U.K. and continental Europe to prevent supply disruptions if the two sides fail to reach a withdrawal agreement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!